Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript
Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript
Seeking Alpha5/8/2026Neutral
TKNO
Alpha Teknova IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$283.62M
P/E Ratio
—
EPS
$-0.31
Beta
0.63
52W High
$6.68
52W Low
$1.91
50-Day MA
$4.68
200-Day MA
$4.01
Dividend Yield
—
Profit Margin
-41.10%
Forward P/E
—
PEG Ratio
—
About Alpha Teknova Inc
Alpha Teknova Inc (TKNO) is a leading entity in the synthetic biology industry, specializing in the development of essential biological reagents and supplements that facilitate advancements in life sciences research and biomanufacturing. The company's innovative offerings are integral to high-demand sectors, including vaccine development, cell and gene therapy, and diagnostic testing, underscoring its commitment to quality and superior customer support. With a robust biotechnology foundation and a focus on innovation, Alpha Teknova is well-positioned to capitalize on growth opportunities within the rapidly evolving life sciences market, enhancing its appeal to institutional investors seeking strategic investments.
Fundamentals
| Revenue (TTM) | $41.80M |
| Gross Profit (TTM) | $14.22M |
| EBITDA | $-9.47M |
| Operating Margin | -38.80% |
| Return on Equity | -23.90% |
| Return on Assets | -9.29% |
| Revenue/Share (TTM) | $0.78 |
| Book Value | $1.21 |
| Price-to-Book | 4.42 |
| Price-to-Sales (TTM) | 6.94 |
| EV/Revenue | 7.1 |
| EV/EBITDA | -6.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 13.10% |
| Shares Outstanding | $53.61M |
| Float | $10.88M |
| % Insiders | 9.32% |
| % Institutions | 84.73% |
Historical Volatility
HV 10-Day
51.58%
HV 20-Day
72.38%
HV 30-Day
84.66%
HV 60-Day
86.63%
HV Rank
67.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($9.00 target)
4
Buy2
HoldLatest News
Teknova Reports First Quarter 2026 Financial Results
First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year Company reaffirms 2026 revenue guidance of $42-44 million
GlobeNewsWire5/6/2026Neutral
Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, following the close of market.
GlobeNewsWire4/22/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TKNO and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/16/2026